Vaginitis is one of the most common reasons women visit a healthcare provider,2 with Bacterial vaginosis (BV) and Candida vaginitis (CV) being two of the most frequent causes of infection.3 Clinicians have traditionally relied on less precise methods such as microscopy, pH testing and clinical observation to diagnose these conditions, yet these methods lack precision.4,5,6 Accurate vaginitis diagnosis is a cornerstone of effective treatment, yet misdiagnosis of this condition is close to 50%, raising the risk of recurrence.7
“Compared to traditional methods, the cobas® BV/CV test can help improve diagnostic accuracy for women affected by vaginitis, addressing a critical need in women’s health,” said Brad Moore, President and CEO, Roche Diagnostics North America. “By expanding our sexual-health portfolio to include comprehensive results for the most common conditions from a single sample, we can streamline care to help patients receive the right treatment faster.”